Abstract: The compounds of the formula (I) ##STR1## in which R.sub.1 is C.sub.1 -C.sub.8 -alkyloxy, allyloxy, allylamino, di(C.sub.1 -C.sub.4 -alkyl)-amino, diallylamino, a 5-membered to 7-membered nitrogen containing heterocyclic group with the nitrogen atom linked to the triazine ring, or a group of the formula (II), ##STR2## R.sub.2 is hydrogen, O, OH, NO, CH.sub.2 CN, C.sub.1 -C.sub.8 -alkyl, allyl, benzyl, C.sub.1 -C.sub.8 -acyl, C.sub.1 -C.sub.18 -alkyloxy, C.sub.5 -C.sub.12 -cycloalkyloxy or OH-monosubstituted C.sub.2 -C.sub.4 -alkyl, R.sub.3 and R.sub.5 independently are hydrogen, C.sub.1 -C.sub.12 -alkyl, C.sub.5 -C.sub.12 -cycloalkyl, C.sub.7 -C.sub.9 -phenylalkyl, tetrahydrofurfuryl, C.sub.2 -C.sub.4 -alkyl monosubstituted by OH, by C.sub.1 -C.sub.4 -alkyloxy or by di(C.sub.1 -C.sub.4 -alkyl)amino, or a group of the formula (III) ##STR3## with R.sub.2 as defined above, R.sub.4 is hydrogen, C.sub.1 -C.sub.

Abstract: The invention concerns a method for treating and preventing secondary effects of hyperinsulinemia by application of insulin-like growth factor I (IGF I), and pharmaceutical compositions comprising IGF I which are useful for this purpose.

Abstract: Tetrachloro-2-cyanobenzoic acid alkyl esters of formula ##STR1## wherein R is C.sub.1 -C.sub.5 alkyl, can be very conveniently prepared by (a) reacting the ammonium salt of tetrachloro-2-cyanobenzoic acid, in the presence of water and an inert organic solvent, with a hydroxide of formula MOH, wherein M is Na or K, and removing the ammonia evolved, and(b) reacting the resultant salt of the formula ##STR2## wherein M is as defined above, with at least 1 mole of a dialkyl sulfate of formula SO.sub.2 (OR).sub.2 or an alkyl halide of formula RHal, wherein R is as defined above and Hal is Cl, Br, I or F, also in the presence of water and an inert organic solvent.

Abstract: Curable compositions comprise(A) a polyglycidyl ether of a polyhydric phenol,(B) a polyglycidyl ether of a polyhydric alcohol,(C) a nitrogen-containing latent hardener for epoxide resins and(D) as cure accelerator dispersed as a powder in the composition, a solid solution of a polymeric phenol with an aliphatic polyamine having two or more amine groups, each of the amine groups being tertiary and at least two of the amine groups being dimethylamino groups.The compositions are useful as adhesives, sealants, laminating resins and coatings.

Abstract: Pharmaceutical preparations for topical, i.e. dermal, application that contain as active ingredient a compound of the formula I ##STR1## especially 2-hydroxy-5-[(RS)-1-hydroxy-2-[[(RS)-1-(p-methoxyphenyl)-prop-2-yl]-amino] -ethyl]-formanilide (formoterol), or one of its pharmaceutically acceptable salts, especially its semifumarate, are proposed for the treatment of inflammatory skin diseases.

Abstract: Linear polyether resins containing 100 to 1 mol % of the repeating structural unit of formula I ##STR1## and 99 to 0 mol % of the repeating structural unit of formula II ##STR2## wherin A is a linear unsubstituted or methyl-substituted alkylene group containing 1 to 100 carbon atoms in the linear alkylene chain, X denotes bridging groups as defined in claim 1, and Y is an aromatic radical of a divalent phenol as defined in claim 1, are thermoplastics with high glass transition temperatures and excellent mechanical strength properties.

Abstract: An epoxy resin composition comprising an epoxy resin which is solid at room temperature and contains on average more than epoxy group per molecule, and a quaternary morpholinium salt as advancement catalyst.When advanced with compounds containing two phenolic hydroxyl groups, these compositions give excellent products of low viscosity which are suitable, for example, for use in powder resin coating.

Abstract: The invention relates to pharmaceutical compositions containing synthetic, substantially pure phosphatidyl serine and phosphatidyl choline and a substance or a mixture of substances having biological activity. The invention also relates to mixtures comprising synthetic, substantially pure phosphatidyl serine and phosphatidyl choline, and also to processes for the manufacture of the pharmaecutical compositions, and the use thereof.

Abstract: Compounds of formula I ##STR1## wherein A, X.sub.1, X.sub.2, X.sub.3, X.sub.4, Y, Z and R.sub.1 to R.sub.6 have the meanings given in the description, have valuable pharmaceutical properties and are effective especially against tumors. They are prepared in a manner known per se.

Abstract: Described is an isoelectric focusing electrophoretic process for the separation and purification of an amphoteric or neutral chemical compound from one or more electrically charged chemical compound(s). Said process is illustrated below at the example of the purification of a protein from contaminating proteins and salts. It may be carried out in an apparatus especially designed therefor, e.g. an apparatus as depicted in FIG. 1. Said apparatus and various modifications thereof are also claimed. The mixture to be separated is present within a hydraulic flow in chamber 8. Cylinders 5 and 12 contain immobilized pH-gradients or are replaced by amphoteric isoelectric pH-membranes. Each of said pH-gradients and pH-membranes has conductivity and both buffering and titrant capacity in its pH-interval.

Abstract: Deoxyribonucleic acid (DNA) molecules consisting of or recombinant DNA molecules containing transcription enhancers from murine cytomegalovirus (MCMV) which can be used to enhance the transcription of structural genes in eukaryotic cells.

Abstract: Compounds of the formula ##STR1## in which R.sub.1 is lower alkyl substituted by hydroxy or by protected hydroxy, R.sub.2 represents carboxy or functionally modified carboxy, R.sub.3 is hydrogen, amino, mono- or di-substituted amino, carbamoyl, hydroxy, protected hydroxy, carbamoyloxy, lower alkoxy, halogen, lower alkanoyl, sulphamoyl or heteroarylthio, each of R.sub.4 and R.sub.5, independently of the other, represents hydrogen, lower alkyl, hydroxy, protected hydroxy, lower alkoxy, halogen, amino, protected amino, lower alkanoylamino or carbamoyl, or R.sub.4 and R.sub.5 together represent methylenedioxy, Y represents a group of the formula --O--, --S-- or --NR.sub.6 --, R.sub.6 is hydrogen or lower alkyl, A.sub.1 represents lower alkylene or unsubstituted or substituted phenylene and A.sub.2 represents a direct bond or lower alkylene, and salts of such compounds, have antibacterial activity. The compounds of the formula I are manufactured by processes that are known per se.

Abstract: Polyglycidyl ethers which are obtainable by reacting acetophenone with 0.7 to 1.4 mol of formaldehyde per mol of acetophenone, in the presence of an alkaline catalyst and in the temperature range from 50.degree. to 100.degree. C., to a carbonylated acetophenone/formaldehyde resin, hydrogenating said carbonylated resin to a modified hydroxylated acetophenone/formaldehyde resin, subsequently converting said resin with epichlorohydrin, in the presence of a phase transfer catalyst, into the corresponding polychlorohydrin ether, and dehydrochlorinating said ether with a base, are suitable for use as epoxy resins, for example for the preparation of powder coating compositions having good resistance to chemicals and good adhesion.

Abstract: The L-arginine salt of N-(D)-{[2-(2,6-dichlorophenylamino}phenyl]acetyl]aspartic acid, represented by the formula ##STR1## in which AmH .sym. represents the cation derived from L-arginine Am of the formula ##STR2## and its hydrates exhibit and excellent water-solubility and a physiologically favorable pH value and also a pleasant taste in aqueous solutions and are therefore excellently suitable for enternal and parenteral forms of administration. It is manufactured by reacting L-arginine with D-{[2-(2,6-dichlorophenylamino)phenyl]-acetyl}aspartic acid.

Abstract: The invention relates to novel hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds of formula ##STR1## in which the variable R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, alk, X, Z, m, n and p, the dotted line and the substituents of the ring A have the meanings indicated in the specification and in the claims, and to their tautomers and/or salts. These compounds can be used as pharmaceutical active ingredients and can be prepared in a manner known per se.

Abstract: Novel nonionic perfluoroalkylthioglycosides of the formula, R.sub.f -E-S-saccharide are described, wherein R.sub.f is a straight or branched chain perfluoroalkyl of 1 to 18 carbon atoms or said perfluoroalkyl substituted by perfluoroalkoxy of 2 to 6 carbon atoms, E is a connecting group, and the saccharide is a mono-, di-, or higher oligosaccharide, comprising 1 to 30 units of 5, 6 or 7 carbon-membered sugars.

Abstract: The invention relates to compositions comprising 20-80% of a vinyl chloride homopolymer (PVC) and 80-20% of at least one copolymer selected from the group consisting of polystyrene/polyethylene/butylene, acrylate/rubber, acrylate/rubber/styrene, acrylonitrile/styrene/acrylate, ABS, NBR, NAR, SAN, EVA and modified EVA, which compositions are stabilized with at least one tin compound of formula(n-C.sub.12 H.sub.25).sub.2 Sn[S(CH.sub.2).sub.n COOR].sub.2 (I) or(n-C.sub.12 H.sub.25)Sn[S(CH.sub.2).sub.n COOR.sup.1 ].sub.3 (II)or with a mixture of compounds of formulae I and II, wherein n is 1 or 2 and R and R.sup.1 are each independently of the other C.sub.6 -C.sub.18 alkyl. These compositions have improved heat storage properties and are particularly suitable for fabricating sheets and hollow bodies for use in the automotive industry.

Abstract: Described is a novel process for the introduction of an organic acyl radical selectively at the nitrogen atom of the amino group of desferrioxamine B or of a partially O-acylated derivative thereof. It comprises treating a derivative of desferrioxamine B, in which the amino nitrogen and the hydroxy oxygen of at least one of the hydroxamic acid groupings carries an organic silyl group, with an organic acylating agent and then removing the silyl groups present. The novel N- and O-silylated starting materials can be manufactured, preferably in situ, by reacting an appropriate derivative of desferrioxamine B that has at least one hydroxy group and the amino group in free form, with an organic silicon halide.

Abstract: The invention relates to azetidin-2-ones of the formula ##STR1## wherein R.sub.a represents hydroxy-lower alkyl, R.sub.1 represents hydrogen, an organic radical bonded by a carbon atom to the ring carbon atom or an etherified mercapto group, R.sub.2.sup.A together with the carbonyl group to which it is attached is a protected carboxyl group and Z' is oxygen, sulfhur or an optionally substituted methylidene group, functional groups in the radicals R.sub.a, R.sub.1 and Z' optionally being in protected form. The azetidinones are useful intermediates for the preparation of penem antibiotics.

Abstract: Sterically hindered cyclic amines which are substituted by a photoactivatable acyl group at the basic nitrogen atom can be deacylated by irradiation with UV light. This is advantageous if the basicity of the amines proves troublesome during application. Examples of such photoactivatable acyl groups are phenylglyoxyl, phenylacetyl or naphthylacetyl groups.